



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/964,277	09/25/2001	Ralf M. Luche	200125.434	9940
500	7590	09/27/2005	EXAMINER	
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE SUITE 6300 SEATTLE, WA 98104-7092			YU, MISOOK	
		ART UNIT	PAPER NUMBER	
			1642	

DATE MAILED: 09/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/964,277	LUCHE ET AL.	
	Examiner	Art Unit	
	MISOOK YU, Ph.D.	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 19 May 2005.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 51 and 55-68 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) 51 and 56 is/are allowed.
- 6) Claim(s) 55,57,58 and 63 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: Exhibit A (5 pages).

DETAILED ACTION

Response to Amendment

The amendment filed on 5/19/2005 has been entered, and the finality of that action is withdrawn, and the prosecution is re-opened for the following reasons:

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 55, 57, 58, and 64 are rejected under 35 U.S.C. 102(e) as being anticipated by either WO 02/10363 (IDS AM filed on 08/12/2002, priority date of 10 August 2000 to US Provisional 60/224,309).

Claims 55, 57, 58, and 64 are drawn to an isolated polypeptide encoding a polypeptide encoded by the polynucleotide at least 90% identical to SEQ ID NO: 20, wherein the polypeptide comprises an amino acid sequence VHCLAGISRS (SEQ ID NO:16), wherein the polypeptide has phosphatase activity on the activated MAP-kinase.

WO 02/10363 (US Provisional 60/224,309) discloses an isolated polypeptide encoding a polypeptide encoded by the polynucleotide at least 90% identical to the instant SEQ ID NO: 20, wherein the polypeptide comprises an amino acid sequence

SEQ ID NO: 16, and also teaches vector comprising the polynucleotide, and host cell comprising the vector at pages 34-38. Note the attached Exhibit A (sequence alignment).

The specification at page 12, 1st full paragraph discloses that the instant SEQ ID NO:16 is the domain that contains the active site. Since the polynucleotide sequence encoding the phosphope of the prior art contains the instant SEQ ID NO:16 as evidenced by the sequence alignment, the protein encoded by the polynucleotide of the prior art inherently has the claimed functional characteristic in view that the structure of the claimed invention and the prior art are the same.

Allowable Subject Matter

Claims 51 and 56 are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



MISOOK YU, Ph.D.
Examiner
Art Unit 1642

Exhibit A 1 of 5

Db	1801	GCAGCACTTACAGTCGTTCTCATCAGAGATCGCTTGGAACTACAACTCC	1860	Db	2881	CCCTACACATTCCACGTGCTACTAAGAGATCTCAATAATTAGCTTGTCCGACC	2940
Qy	1697	ACTACTGTGATGGGACCAACAAGCTTCCAGTTCCCGTCTGGACTATCGAG	1756	Qy	2777	CTTCATAGTACCTTACGGCTGAGACTGAGCGCTGGGGCAGGTAGTACCC	2846
Db	1861	ACTACTGTGATGGGACCAACAAGCTTCCAGTTCCCGTCTGGACTATCGAG	1756	Db	2941	CTTCATAGTACCTTACGGCTGAGACTGAGCGCTGGGGCAGGTAGTACCC	3000
Qy	1757	CAGACTCCGAAACAGCTCTATAGGGAGGGAGATCCCAGAGCTGGAGACC	1816	Qy	2837	TGTTGGACAGACCTAGTGTAAATCCAGAGATGATCTCCAGCTGAGCTGGAGC	2896
Db	1921	CAGACTCCGAAACAGCTCTATAGGGAGGGAGATCCCAGAGCTGGAGACC	1816	Db	3001	TGTTGGACAGACCTAGTGTAAATCCAGAGATGATCTCCAGCTGAGCTGGAGC	3060
Qy	1817	GCAGACCTCAGAGGAGCCAGAGGAGATSCATCGTCAACCCACCACTGGC	1876	Qy	2897	CAACCCAGCTCTACGGAGGGAGCTGAGCTGAGTGGGGGGAGGAGCATT	2956
Db	1981	GCAGACCTCAGAGGAGCCAGAGGAGATSCATCGTCAACCCACCACTGGC	1876	Db	3061	CAAAACACGCTCTACGGAGGGAGCTGAGCTGAGTGGGGGGAGGAGCATT	3120
Qy	1877	ACGCCAGAGGTCTTATTCATCTGAGCTGAGTGGGGGGAGGAGCATTAC	1936	Qy	2957	ACGCCCTGGAGGTACTTGAGCAACGAGACTCAGAGGAAGGGGG	3016
Db	2041	ACGCCAGAGGTCTTATTCATCTGAGCTGAGTGGGGGGAGGAGCATTAC	1936	Db	3121	ACGCCCTGGAGGTACTTGAGCAACGAGACTCAGAGGAAGGGGG	3180
Qy	1937	CAACCCAGCTCTACGGAGGGAGCTGAGCTGAGTGGGGGGAGGAGCATT	1996	Qy	3017	CTTGACCACTACATCTGAGCTGAGCTTCTGGGG	3076
Db	2101	CAACCCAGCTCTACGGAGGGAGCTGAGCTGAGTGGGGGGAGGAGCATT	1996	Db	3181	CTTGACCACTACATCTGAGCTGAGCTTCTGGGG	3240
Qy	1997	CTGGCTTAAGGTTGGACTGAGATACTTGGGCCCCAGACCTTACCCCTCCTG	2056	Qy	3077	AGTCACACTTTCGACAACTCAACTGCTGATGAGCTGAGCTGAGCTGAGC	3136
Db	2161	CTGGCTTAAGGTTGGACTGAGATACTTGGGCCCCAGACCTTACCCCTCCTG	2056	Db	3241	AGTCACACTTTCGACAACTCAACTGCTGATGAGCTGAGCTGAGCTGAGC	3300
Qy	2057	ACCAAGAGCTGTTTTCAGAGAGCTCTACACTCTACTCTGCTCAGGCTAC	2116	Db	3137	GAGTAATTCTTCTCAGGTTATGAGAGAAGGGAAACTCTGAGATTCAGC	3196
Db	2221	ACCAAGAGCTGTTTTCAGAGACTCTTCACTCTACTCTGCTCAGGCTAC	2116	Db	3301	GAGTAATTCTTCTCAGGTTATGAGAGAAGGGAAACTCTGAGATTCAGC	3360
Qy	2117	GGGGCACTGCGCACTACTCTGCGCACAGCAGCTGCCAGCTGGAGCAA	2176	Qy	3187	TAACACCAAGGAGCTGGAGACATCAGGTTAGCTAAGGTGGAGGCTAACAGTC	3256
Db	2281	GGAGGAGCTGCGCACTACTCTGCGCACAGCAGCTGCCAGCTGGAGCAA	2176	Db	3361	TAACACCAAGGAGCTGGAGACATCAGGTTAGCTAAGGTGGAGGCTAACAGTC	3420
Qy	2177	GTCTATTCTGCGCACTGCGCACAGCAGCTGCCAGCTGGAGCTGAGCTG	2236	Qy	3257	TACCTCCCTTTTAAATCAGGTTAAATGGATGTTGACATCTTAAATAAA	3316
Db	2341	GTCTATTCTGCGCACTGCGCACAGCAGCTGCCAGCTGGAGCTGAGCTG	2236	Db	3421	TACCTCCCTTTTAAATCAGGTTAAATGGATGTTGACATCTTAAATAAA	3480
Qy	2237	CATGAGAGGAGCCCTTGTAAAGCAGTAAACCCAGAGCTCCAAATGAGATTG	2296	Qy	3317	AGATGAACCTGGTTTC	3332
Db	2401	CATGAGAGGAGCCCTTGTAAAGCAGTAAACCCAGAGCTCCAAATGAGATTG	2460	Db	3481	AGATGAACCTGGTTTC	3496
Qy	2297	GGAGGAGCTGTCAGAGAGCTGAGGAGAGCTGGGAGGAGCTGGCT	2356				
Db	2461	GGAGGAGCTGTCAGAGAGCTGAGGAGAGCTGGGAGGAGCTGGCT	2520				
Qy	2357	AGCTTTCGGGAGCATGAGAAATCTGAGGTCTGAGAGAGACCTGTT	2416				
Db	2521	AGCTTTCGGGAGCATGAGAAATCTGAGGTCTGAGAGAGCTGGCT	2500				
Qy	2417	CTTAACTGAACTTTCGTCAGAGAAATCTGAGGTCTGAGAGAGCTGGCT	2476				
Db	2581	CTTAACTGAACTTTCGTCAGAGAAATCTGAGGTCTGAGAGAGCTGGCT	2476				
Qy	2477	ATGAGCATACATATATTGGAATAGGAGTATGGTGTAAACACAGGTTGATC	2336				
Db	2641	ATGAGCATACATATATTGGAATAGGAGTATGGTGTAAACACAGGTTGATC	2700				
Qy	2537	AACCCAGTGTACTCTTCACTCTTCACTCTTCACTCTC	2956				
Db	2701	AACCCAGTGTACTCTTCACTCTTCACTCTC	2760				
Qy	2597	AAATGGGGGAGCTGAGTAAACCCCTAGACCGAGAAACATTATTGAGT	2656				
Db	2761	AAATGGGGGAGCTGAGTAAACCCCTAGACCGAGAAACATTATTGAGT	2620				
Qy	2657	GAATTAACATCTCTCTGCTCTAAAGCAGTGTCTTGTGAGACAAATC	2716				
Db	2821	GAATTAACATCTCTCTGCTCTAAAGCAGTGTCTTGTGAGACAAATC	2880				
Qy	2717	CCCTACCAATTCCACGGTGTCTACTAAGAGATCTCAATAATTAGCTTGT	2776				

RESULT 3

ABK14474

ID

ABK14474

AC

ABK14474;

XX

DE

Human-protein-phosphatase_7 (PP7) cDNA sequence.

X

XX

三
五
七

Page 7

Exhibit A 485

PI-0198 P

<223> Incyte ID No: 7480570CB1

<400> 2

→ gaaaagaaga tgaggaggag agcgacggga cgggacgcga gccggagcgc agcccccctc 60
 tcggctccgc ggcggcgcct cgcaagtccg ggaggcgagg gggggcccag gggagacgcc 120
 gtgacaactt tcgtttccct ctgagggaaat tgggaggtcg gccggcccaa aagcttcag 180
 tccagtgtaa agctgttggaa gcgcgggagc aaaggtaaag aatgtatgtaa tgccgtggct 240
 gctccaaagc atctttgtt gtggaatgggt tattccagtc attcttttat gaatcaaatg 300
 tgaggggctg ctttggac ggagtcctt gcaagagcac atcaacggga aagagaaaaga 360
 gacattcaact tggagggctc ttgtgtaaaa tgggttaac ttccttttg ccagtccacca 420
 ccagcctgac ctcatacact tttagtacaa tggagtggtc gaccccttga gcacaccacc 480
 attacatcat cgtggcaaat taaaagaaggaa ggtggaaaaa gaggacttat tggtgtcatg 540
 gcccattgaga tgatttggaaac tcaaattgtt actgaggggt tgggtggctct gctggaaagt 600
 ggaacggaaa aagtgtgtc aattgtatgc cggccatttgc tggaaatacaa tacatcccc 660
 atttttggaaag ccattaataat caactgtcc aagcttatga agcgaagggt gcaacaggac 720
 aaagtgttaa ttacagagct catccagcat tcagcgaaac ataagggttga cattgattgc 780
 agtcagaagg ttgttagtta cgatcaaagc tcccaagatg ttgcctctct ctcttcagac 840
 tggttctca ctgtacttct gggtaaactg gagaagagct tcaactctgt tcacctgctt 900
 gcaggtgggt ttgctgagtt ctctcggtt ttccctggcc tctgtgaagg aaaatccact 960
 ctatccccta cctgcatttc tcagccttgc ttacctgttgc ccaacattgg gccaacccga 1020
 attctccca atctttatct tggctgcccag cgagatgtcc tcaacaaggaa gctgtatgcag 1080
 cagaatggga ttggttatgt gttaaatggcc agcaataacct gtccaaagcc tgactttatc 1140
 cccgagtctc atttcctgcg tggcctgtg aatgacagct ttgttgagaa aattttggcg 1200
 tggttggaca aatcaatgttca tttcatttggaa aagcaaaaag ctccttgcg atgtgttcta 1260
 gtgcactgtt tagctggat ctccgcgtcc gcccacatcg ctatcgccat catcatgaag 1320
 aggatggaca tgcatttgcg tgaagcttac agatttgtga aaaaaaaaaaag acctactata 1380
 tctccaaact tcaattttctt gggccaaactc ctggactatg aagaagaatg taagaaccag 1440
 actggagcat cagggccaaa gagcaaaactc aagctgtgc acctggagaa gccaatgaa 1500
 cctgtccctg ctgttcaga ggggtggacag aaaaggcgaga cggcccttcg tccaccctgt 1560
 gccgactctg ctacccatcaga ggcagcaggaa caaaggcccc tgcatcccg cagcgtgccc 1620
 agcgtgcccgc gctgcagcc gtcgtgttta gaggacagcc cgctggtaca ggcgtcagt 1680
 gggctgcacc tgcctcgaga caggctggaa gacagcaata agctcaagcg ttccctctt 1740
 ctggatataca aatcaatgttca atattcagcc agcatggcag catccttaca tggcttctcc 1800
 tcattcagaag atgctttggaa atactacaaa cttccacta ctctggatgg gaccaacaag 1860
 ctatgccagt tctccctgt tcaggaacta tcggagcaga ctcccgaaac cagtcctgtat 1920
 aaggagggaaag ccagcatccc caagaagctg cagaccggca ggccttcaga cagccagagc 1980
 aagcgattgc attcggtcag aaccagcagc agtggcaccg cccagagggtc ctttttatct 2040
 ccactgcattc gaagggtggag cgtggaggac aattaccaca ccagcttc tttcgccctt 2100
 tccaccagcc agcagcacct cacgaagtct gctggcctgg gccttaagggtt ctggcactcg 2160
 gatatcttgg ccccccagac ctctaccctt tccctgacca gcaacttgcgat ttttggccaca 2220
 gagtcctcactt acttttactt tgcctcgaggc attcacggag gcaacttgcgat ttactctgtt 2280
 tacagctgca gccagctgca cacttgcgca gaccaacttgc attcacggatc caggccggcag 2340
 aagccaatgttca ctcgcggcgg agctggcatg aagagagccc ctttggaaaag 2400
 cagtttaaac gcagaagctg ccaaataggaa ttggagagaa gcatcatgtc agagaacagg 2460
 tcacgggaag agctggggaa agtggcactg cagtcacttgc ttccggccag catggaaatc 2520
 attgagggttctt cctgagaaga aagacacttgc tgacttctat agacaattttt tttttttgtt 2580
 tcacaaaaaa attccctgttca aatctgaaat atatataatgtt acatacatat atattttgg 2640
 aaaatggagc tatgggttca aagcaacagg tggatcaacc cagttgttac ttccttaaca 2700
 tctgcatttgc agagatcagc taataacttctt ctcaacaaaaa atggaaaggcc agatgttagg 2760
 atcccccccta gacggaggaa aaccatttttca ttcactgttca tacacatctt cttgttctt 2820
 aaaaaggcaag tgcattttgggt gttggaggac aaaatcccttccatccatc cgttgcgttca 2880
 ctaagagatc tcaatatttgcgttcc ggacccttcc atagtcaccc ttgcgtgttca 2940
 gactgagccca gcttgggggtt caggtaggttca gacccttgcgttca gggacagagcc ctagtggtaa 3000
 atccaagaga aatgtatccca tccaaagctg attcacaatccatc ccacgctcac ctgacagccg 3060
 agggacacca gcatcactctt gctggacggca ccattagggg ctttgcgttca gtcgttcc 3120
 gagcaaaaccc agtacacttgc acaggaaatgtt cggggcttttgc accactacca tatctggtag 3180
 cccatccatc aggcatttgcgttca aataggttgc tagctgttca cacttttgcgttca accaatttca 3240
 actgtctatg cacaatccatc cctgtggccctt agatggagat aatttttttt tcttcttgcgttca 3300
 tttatgttca aatcaatgttca tcaatccatc caccaggaaac ctggcaacat 3360
 cacgattttaa gctaaagggttgc gggggcttgcgttca ggttgcgttca ccccttttgcgttca aatcaatgttca 3420
 attgtttaaa atgggatttgcgttca aatcaatgttca aacttgcgttca aagccaaat 3480

5g₅₋₁

PI-0198 P

gtgaatttat	ttggggttgg	agcagagccag	cagcaccccttc	aaattcttag	ccaaaggcaga	3540
tgttttgcc	cttctgctt	cactgcattgg	atacagtgg	taaaaatgtaa	taatatggca	3600
gaattttata	ggaaacttcc	tagggaggtt	aattatggaa	agattaagaa	aggtacaaat	3660
tgctgaggag	aagcaggaaa	cctgtttctt	tagtggttt	tatcccctcg	gcatgcgtg	3720
gggctgtatgt	ttctatgatt	gcctcagact	ttcacatttt	ctagta		3766

卷之三